A summary of our ongoing clinical trials can be found below
Clinical trials are a part of a carefully planned and legally required process to move a potential new drug from the discovery process through to market availability. Our ongoing clinical trial programs are outlined below.
Not Currently Enrolling
Our global Phase III program aims to differentiate ridinilazole from vancomycin, the current standard of care for C. difficile infection. The program is designed to determine the safety and efficacy of ridinilazole for use as first-line therapy for the treatment of initial and recurrent C. difficile infection.
This effort is funded in part with federal funds of up to $72.5 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, under contract number HHSO100201700014C.
For our latest update related to the Phase III program, please refer to our press release dated August 11, 2021.
Our Phase III program includes an additional study to determine the safety of ridinilazole as compared to vancomycin, the current standard of care for C. difficile infection, in adolescents 12 through 17 years of age. The trial is expected to enroll approximately 40 patients.
For more information for patients, visit www.ricodifycdiff.com.
For our information on clinicaltrials.gov, please visit Ri-CoDIFy 3.